Correlation Between NervGen Pharma and Mineralys Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both NervGen Pharma and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NervGen Pharma and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NervGen Pharma Corp and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on NervGen Pharma and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NervGen Pharma with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of NervGen Pharma and Mineralys Therapeutics,.

Diversification Opportunities for NervGen Pharma and Mineralys Therapeutics,

-0.24
  Correlation Coefficient

Very good diversification

The 3 months correlation between NervGen and Mineralys is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding NervGen Pharma Corp and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and NervGen Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NervGen Pharma Corp are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of NervGen Pharma i.e., NervGen Pharma and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between NervGen Pharma and Mineralys Therapeutics,

Assuming the 90 days horizon NervGen Pharma Corp is expected to generate 1.02 times more return on investment than Mineralys Therapeutics,. However, NervGen Pharma is 1.02 times more volatile than Mineralys Therapeutics, Common. It trades about 0.0 of its potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about -0.08 per unit of risk. If you would invest  203.00  in NervGen Pharma Corp on November 29, 2024 and sell it today you would lose (9.00) from holding NervGen Pharma Corp or give up 4.43% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

NervGen Pharma Corp  vs.  Mineralys Therapeutics, Common

 Performance 
       Timeline  
NervGen Pharma Corp 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days NervGen Pharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, NervGen Pharma is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders.
Mineralys Therapeutics, 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

NervGen Pharma and Mineralys Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with NervGen Pharma and Mineralys Therapeutics,

The main advantage of trading using opposite NervGen Pharma and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NervGen Pharma position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.
The idea behind NervGen Pharma Corp and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk